bilaterals.org logo
bilaterals.org logo

medicines


India-UK FTA: Public health must get priority in trade talks
The India-UK FTA is expected to promote the free movement of goods and services, significantly impacting access to pharmaceuticals, medicines, and devices. FTAs pose new challenges for public health activists in India, necessitating appropriate actions to monitor and advocate for change. This is particularly important for public health advocates concerned with the broader commercial determinants of health.
I-EU CEPA negotiations hijack democratic rights and ignore potentional impacts on society
Indonesia for Global Justice (IGJ) and the Indonesia AIDS Coalition (IAC) criticized the I-EU CEPA, which hijacked the people’s rights to democracy while ignoring the negotiations’ wider impact. The I-EU CEPA negotiations lacked transparency, ignored public aspirations, and did not allow for meaningful participation from civil society groups.
India’s newly amended patent rules threaten affordable medicines in the Global South
It is no coincidence that just five days before the amendments were announced, India signed a Free Trade Agreement with the European Free Trade Association.
Implications for intellectual property rights following Switzerland and India’s new free trade agreement
The FTA contains various provisions on the protection of intellectual property rights that will influence trade between Swiss and Indian companies.
Swiss trade deal: Is India changing its tune on pharma patents?
Intellectual property protection for the Swiss pharmaceutical industry has been a key sticking point in negotiations on a free trade agreement with India. Now there seems to be a breakthrough in talks after 16 years. What’s changed?
Thorny clause in ripening India-European Free Trade Association deal may hit generic drug industry
The clause in the draft free trade agreement text could delay access to affordable, generic versions of patented drugs in India by a minimum of six years, according to documents.
New patent rules in India-UK trade agreement will prioritise pharmaceutical profit over public health
The “TRIPS-Plus” provisions in the India-UK Agreement are a dangerous attempt to increase the power of pharmaceutical companies by placing profits before public health.
Letter: Civil society calls on UK Prime Minister to ensure UK-India free trade agreement does not threaten access to affordable medicines
MSF and over 50 UK-based civil society organisations and individuals sent this open letter to United Kingdom Prime Minister, urging him to commit that the UK-India Free Trade Agreement will not gut the public health safeguards that are in India’s intellectual property laws.
AfCFTA: More free trade? For whose benefit?
So what does this trade deal mean for ordinary Africans in a time of deep climate, economic and food crises?
Kenya, Indonesia to sign preferential trade agreement
Kenya and Indonesia yesterday signed four bilateral agreements on food security, mining, renewable energy and health following talks between President William Ruto and Indonesia’s Joko Widodo.
EU trade deals risk affordability of generic medicines for Global South
The disproportionate intellectual property protections the bloc proposes could threaten the affordability of generics that countries like India and Indonesia export to poorer nations.
Proposed EU-India FTA
Can India protect its development objectives by signing a free trade agreement with an unequal partner with different ambitions?
Clamour against United Kingdom’s free-trade negotiator
Groups from India and nearly 40 countries express concern about a leaked chapter from the proposed FTA that they say appears to represent ‘a wish list’ of the pharmaceutical industry.
India-UK FTA leaked draft reveals nobody’s gain except big pharma
India - UK FTA provisions favor neither India nor the UK except the pharma industry in a big way. It defeats the firm stand taken by the Indian PM three years ago when he decided to pull out of the RCEP against the corporate interests over people’s lives.
MSF responds to UK’s disastrous proposal on intellectual property in UK-India Free Trade Agreement
UK IP demands contain provisions that would drastically harm access to affordable, lifesaving generic medicines from India, upon which millions of people around the world rely.
WTO COVID IP negotiating text as of 25/5/2022
Consolidated negotiating COVID intellectual property text as of 25/5/2022
After India-Aus FTA, Indian pharma industry sees global opportunities
After the Comprehensive Economic Cooperation Agreement signed between India and Australia, the domestic pharmaceutical industry is seeing a plethora of opportunities for international trade.
An India-UK trade deal could mean a race to the bottom for Indian workers
On farmers and food, vaccine inequality, climate justice and digital rights, we need to act in solidarity – and not allow trade rules to sacrifice people to corporate profit.
World has moved on from US, EU’s drug monopoly. India and China are changing IP regulations
Even without an IP waiver from the WTO, China and India are leading the challenge to the West’s vaccine monopoly.